Performance of Ir(III)-Based Anticancer Agents in the Treatment of Cisplatin-Resistant Cancer Cells.

The resistance of cancer cells to cisplatin has dramatically blocked the further application of this drug in practical treatment settings. The generation of cisplatin resistance is a complex physiological process, and several mechanisms have been reported for this. New metal-based agents with distinct anticancer mechanisms are still highly desired. In this concept article, we describe Ir(III)-based anticancer agents and their underlying anticancer mechanisms, which could inhibit the proliferation of cisplatin-resistant tumors. This work could be beneficial in developing more effective Ir(III)-based agents to combat cisplatin resistance.